{
  "created_at": "2020-11-13T02:04:24.000Z",
  "updated_at": "2021-01-06T08:25:12.208Z",
  "id": "a672181e-4a85-47b7-93aa-b683f011afff",
  "labels": "current-affairs,2020-11-14",
  "question": "Which potential vaccine candidate of India has completed enrolment of Phase III clinical trials?",
  "option1": "Covaxin",
  "option2": "Covishield",
  "option3": "Covidol",
  "option4": "Covindia",
  "option5": "",
  "answer": "Covishield",
  "explanation": "COVISHIELD, the Covid-19 potential vaccine candidate has recently completed the enrolment of Phase III clinical trials.<br />COVISHIELD has been developed by the Serum Institute of India with a master seed from Oxford University and AstraZeneca. SII has already manufactured 40 million doses of the vaccine and will make the vaccine available by joining hands with ICMR."
}